FDA Approves New Drug for Schizophrenia, Bipolar Disorder

Share this content:
FDA Approves New Drug for Schizophrenia, Bipolar Disorder
FDA Approves New Drug for Schizophrenia, Bipolar Disorder

FRIDAY, Sept. 18, 2015 (HealthDay News) -- A new antipsychotic drug to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration. The drug, Vraylar (cariprazine), is a capsule taken once a day.

The drug's effectiveness in treating schizophrenia was tested in 1,754 patients in three six-week clinical trials. It was shown to reduce schizophrenia symptoms compared to a placebo. The most commonly reported side effects in the schizophrenia trials were tremor, slurred speech, and involuntary muscle movements.

In three three-week trials involving 1,037 bipolar patients, Vraylar reduced disorder symptoms, the FDA said. The most common drug-related side effects in the bipolar disorder trials included tremor, slurred speech, akathisia, dyspepsia, vomiting, drowsiness, and restlessness.

All FDA-approved drugs for schizophrenia and bipolar disorder must carry a black-box warning indicating an increased risk of death if these drugs are used by older people with dementia-related psychosis, the agency noted.

The drug's maker, Forest Labs, and distributor, Actavis Pharma, are based in New Jersey.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »